AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37276067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks (Cohort 1)
Number of subjects: 77
Study 37276067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks (Cohort 2)
Number of subjects: 77
Study 37276084 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy (BA)
Number of subjects: 39
Study 37276086 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted psychotherapy
Number of subjects: 13
Study 37276273 — intervention group
Group type: EXPERIMENTAL
Intervention: MI combined with physical practice of walking
Number of subjects: 30
Study 37276273 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different gait training protocols
Number of subjects: 30
Study 37276451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase 2000 IU/m2 added to courses 1, 2, 5, and 6 of an 8-block chemotherapy protocol.
Number of subjects: 203
Study 37276451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase treatment with allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 203
Study 37276451 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 203
Study 37276451 — intervention group
Group type: COMPARATOR
Intervention: HCT (control group)
Number of subjects: 203
Study 37276451 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and MRD status as independent factors
Number of subjects: 203
Study 37276451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase treatment
Number of subjects: 203
Study 37276496 — intervention group
Group type: EXPERIMENTAL
Intervention: MS2010-SR (anthracycline-free protocol)
Number of subjects: 369
Study 37276496 — intervention group
Group type: COMPARATOR
Intervention: MS2003-SR (modified Berlin-Frankfurt-Muenster ALL-IC2002 protocol with 120 mg/m² anthracycline)
Number of subjects: 369
Study 37276510 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 815
Study 37276510 — intervention group
Group type: COMPARATOR
Intervention: Treatment Choice (TC) - azacitidine, decitabine, or low-dose cytarabine
Number of subjects: 815
Study 37276510 — intervention group
Group type: COMPARATOR
Intervention: Treatment Choice (TC)
Number of subjects: 815
Study 37276510 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (in patients receiving ≥4 cycles)
Number of subjects: 815
Study 37276510 — intervention group
Group type: COMPARATOR
Intervention: Treatment Choice (TC) (in patients receiving ≥4 cycles)
Number of subjects: 815
Study 37276590 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE (AssiSTed EaRly MobIlity for HospitalizeD VEterans) walking program
Number of subjects: 8
Study 37276590 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-STRIDE time periods)
Number of subjects: 8
Study 37276871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab 20 mg/kg intravenously every 2 weeks
Number of subjects: 87
Study 37276871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Number of subjects: 87
Study 37276913 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose quadruple therapy (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Number of subjects: 90
Study 37276913 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose dual therapy (irbesartan 150 mg + amlodipine 5 mg)
Number of subjects: 90
Study 37276937 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern high in ultraprocessed foods (UPF-DP)
Number of subjects: 20
Study 37276937 — intervention group
Group type: COMPARATOR
Intervention: Dietary pattern void of ultraprocessed foods (UN-DP)
Number of subjects: 20
Study 37276947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant follicle-stimulating hormone (rFSH) treatment
Number of subjects: 54
Study 37276947 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-weight women)
Number of subjects: 54
Study 37277078 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-325
Number of subjects: 106
Study 37277078 — intervention group
Group type: COMPARATOR
Intervention: SET
Number of subjects: 106
Study 37277100 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0
Study 37277100 — intervention group
Group type: COMPARATOR
Intervention: Standard reminiscence therapy
Number of subjects: 0
Study 37277217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (LDL-C of <1.8 mmol/L or ≥50% reduction from the baseline)
Number of subjects: 2900
Study 37277217 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity lipid lowering (LDL-C of <2.6 mmol/L or 30%-49% reduction from the baseline)
Number of subjects: 2900
Study 37277219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control therapies
Number of subjects: 5560
Study 37277219 — intervention group
Group type: COMPARATOR
Intervention: Non-rhythm control strategy
Number of subjects: 5560
Study 37277227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 46
Study 37277275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID
Number of subjects: 277
Study 37277454 — intervention group
Group type: EXPERIMENTAL
Intervention: Camonsertib (RP-3500) at a recommended phase 2 dose of 160 mg weekly on days 1-3
Number of subjects: 120
Study 37277703 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 20 ml of bupivacaine 0.25% (n=50)
Number of subjects: 100
Study 37277703 — intervention group
Group type: COMPARATOR
Intervention: Control group with 20 ml saline injection (n=50)
Number of subjects: 100
Study 37277833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus pelvic floor muscle training (PFMT) protocol for 12 weeks, including 6 group sessions of supervised PFMT delivered by a physiotherapist.
Number of subjects: 0
Study 37277833 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet alone for 12 weeks.
Number of subjects: 0
Study 37277833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus PFMT protocol for 12 weeks.
Number of subjects: 0
Study 37277837 — intervention group
Group type: COMPARATOR
Intervention: Home visits by gender-matched community health workers (Arm 1)
Number of subjects: 2152
Study 37277837 — intervention group
Group type: COMPARATOR
Intervention: Gender-segregated, group discussion sessions (Arm 2)
Number of subjects: 2152
Study 37277837 — intervention group
Group type: COMPARATOR
Intervention: Both home visits and group discussion sessions (Arm 3)
Number of subjects: 2152
Study 37277837 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (no intervention)
Number of subjects: 2152
Study 37277877 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline for 3 months
Number of subjects: 60
Study 37277877 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 60
Study 37277878 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up 4 Health (FCU4Health)
Number of subjects: 113
Study 37278122 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm in alert state
Number of subjects: 568
Study 37278122 — intervention group
Group type: COMPARATOR
Intervention: HeartLogic algorithm out of alert state
Number of subjects: 568
Study 37278122 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic alerts
Number of subjects: 568
Study 37278302 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-HIV co-infection
Number of subjects: 116
Study 37278302 — intervention group
Group type: COMPARATOR
Intervention: HBV mono-infection
Number of subjects: 116
Study 37278621 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses (360° virtual reality video)
Number of subjects: 44
Study 37278621 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (control group)
Number of subjects: 44
Study 37278638 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of ATX or LPAR
Number of subjects: 0
Study 37278638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplantar injection of cancer exosomes
Number of subjects: 0
Study 37278638 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of ATX or blockade of LPAR
Number of subjects: 0
Study 37278638 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel in vitro studies
Number of subjects: 0
Study 37278657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder-filling pain positive status (BFP+)
Number of subjects: 429
Study 37278657 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPPS subtype with bladder-filling pain (BFP+)
Number of subjects: 429
Study 37278657 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPPS subtypes
Number of subjects: 429
Study 37278657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain ratings at baseline and 6 months
Number of subjects: 429
Study 37278657 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging post-consumption
Number of subjects: 429
Study 37278682 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV22
Number of subjects: 87
Study 37278682 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV25
Number of subjects: 87
Study 37278682 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV22 and TPV25 combined
Number of subjects: 87
Study 37278684 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigated needle ablation (INA)
Number of subjects: 111
Study 37278690 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health (4-month subscription to the online Goalistics Chronic Pain Management Program)
Number of subjects: 165
Study 37278690 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 165
Study 37278744 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Closing Distal Femoral Osteotomy (MCDFO)
Number of subjects: 22
Study 37278744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Opening Distal Femoral Osteotomy (LODFO)
Number of subjects: 22
Study 37278760 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating sublingual microcirculatory perfusion variables in the therapy plan
Number of subjects: 141
Study 37278760 — intervention group
Group type: COMPARATOR
Intervention: Usual routine care
Number of subjects: 141
Study 37278858 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus low-dose temozolomide (50 mg/m²)
Number of subjects: 81
Study 37278858 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus low-dose temozolomide (50 mg/m²)
Number of subjects: 81
Study 37278879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (AZD1775) 175 mg orally twice a day on days 1-3 and 8-10 of a 21-day treatment cycle
Number of subjects: 80
Study 37278968 — intervention group
Group type: EXPERIMENTAL
Intervention: D-galactose supplementation (1.5 g/kg/day for 6 months)
Number of subjects: 12
Study 37278968 — intervention group
Group type: EXPERIMENTAL
Intervention: D-galactose supplementation
Number of subjects: 12
Study 37278972 — intervention group
Group type: EXPERIMENTAL
Intervention: GB223 (7, 21, 63, 119, or 140 mg)
Number of subjects: 44
Study 37278972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 37278972 — intervention group
Group type: EXPERIMENTAL
Intervention: GB223
Number of subjects: 44
Study 37278999 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health coaching intervention for 12 months with educational materials, automatic blood pressure monitor, scale, pill organizer, and healthy nutrition tools.
Number of subjects: 264
Study 37278999 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus educational materials (control group).
Number of subjects: 264
Study 37278999 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health coaching intervention.
Number of subjects: 264
Study 37278998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary Nail (IMN)
Number of subjects: 850
Study 37278998 — intervention group
Group type: COMPARATOR
Intervention: Sliding Hip Screw (SHS)
Number of subjects: 850
Study 37279000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Number of subjects: 6412
Study 37279000 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-aspirin (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90)
Number of subjects: 6412
Study 37279000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412
Study 37279000 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 6412
Study 37279000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin among poor metabolizers
Number of subjects: 6412
Study 37279000 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-aspirin among poor metabolizers
Number of subjects: 6412
Study 37279009 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 0
Study 37279034 — intervention group
Group type: EXPERIMENTAL
Intervention: New insulin pump
Number of subjects: 0
Study 37279034 — intervention group
Group type: EXPERIMENTAL
Intervention: New glucose sensor
Number of subjects: 0
Study 37279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg BID for 24 hours, then 50 mg BID for 13 days)
Number of subjects: 193
Study 37279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 193
Study 37279301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 37279578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based therapy (mesenchymal stem cells)
Number of subjects: 29
Study 37279602 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral camostat for 7 days
Number of subjects: 216
Study 37279602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 37279641 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM CBT treatment (9-13 sessions)
Number of subjects: 396
Study 37279641 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 396
Study 37279709 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg/kg, twice over 24 h)
Number of subjects: 37
Study 37279709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 37279780 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin (PLD) and cyclophosphamide plus trastuzumab/pertuzumab (HP) followed by nab-paclitaxel and HP.
Number of subjects: 96
Study 37279786 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) defect size ≥ 90% of luminal circumference
Number of subjects: 916
Study 37279786 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) defect size 60%-89% of luminal circumference
Number of subjects: 916
Study 37279786 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) defect size < 60% of luminal circumference
Number of subjects: 916
Study 37279797 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg weekly)
Number of subjects: 22
Study 37279836 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradable Hydrogel for sustained localized delivery of anti-tumor drugs; specific dosage and duration not mentioned.
Number of subjects: 0
Study 37279836 — intervention group
Group type: COMPARATOR
Intervention: Direct intratumoral injection of a drug; specific dosage and duration not mentioned.
Number of subjects: 0
Study 37279840 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman FLX device
Number of subjects: 3000
Study 37279840 — intervention group
Group type: COMPARATOR
Intervention: DOACs
Number of subjects: 3000
Study 37279855 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF; Pregnyl; Organon, Jersey City, NJ) added to standard aGVHD therapy
Number of subjects: 22
Study 37279855 — intervention group
Group type: COMPARATOR
Intervention: Standard aGVHD therapy (methylprednisolone 48 mg/m2)
Number of subjects: 22
Study 37279993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NivoMes, NCT02497508) or nivolumab and ipilimumab (INITIATE, NCT03048474)
Number of subjects: 49
Study 37279993 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of two-specific TCR clusters
Number of subjects: 49
Study 37279999 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir, 480 mg, orally daily (with acyclovir)
Number of subjects: 601
Study 37279999 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir, 900 mg, orally daily (adjusted for kidney function)
Number of subjects: 601
Study 37279999 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 601
Study 37279999 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 601
Study 37280022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime diuretics
Number of subjects: 552
Study 37280022 — intervention group
Group type: COMPARATOR
Intervention: Non-diuretics
Number of subjects: 552
Study 37280026 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney biopsy
Number of subjects: 300
Study 37280029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study among PLHIV and healthcare workers
Number of subjects: 0
Study 37280029 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured survey
Number of subjects: 0
Study 37280029 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of aggregated patient data
Number of subjects: 0
Study 37280029 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of facility implementation of infection prevention and control measures
Number of subjects: 0
Study 37280081 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (RMZ group)
Number of subjects: 103
Study 37280081 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 103
Study 37280082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoserratus and interpectoral plane block combined with general anesthesia (ropivacaine 3.75 mg/mL and clonidine 3.75 µg/mL in 40 mL of 0.9% sodium chloride)
Number of subjects: 164
Study 37280083 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour group (last dose at 07:00 the day prior to surgery)
Number of subjects: 103
Study 37280083 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-hour group (last dose at 19:00 2 days prior to surgery)
Number of subjects: 103
Study 37280116 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab)
Number of subjects: 0
Study 37280116 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough cases
Number of subjects: 0
Study 37280116 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19 breakthrough cases
Number of subjects: 0
Study 37280238 — intervention group
Group type: EXPERIMENTAL
Intervention: GRT-R910
Number of subjects: 0
Study 37280275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) chemotherapy
Number of subjects: 519
Study 37280275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) chemotherapy combined with immunotherapy
Number of subjects: 519
Study 37280417 — intervention group
Group type: EXPERIMENTAL
Intervention: HidroQoL questionnaire
Number of subjects: 529
Study 37280508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 150
Study 37280508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP) ventilation
Number of subjects: 150
Study 37280508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study 37280508 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HFNC, nCPAP, and usual care)
Number of subjects: 150
Study 37280530 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 0
Study 37280530 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized COVID-19 patients
Number of subjects: 0
Study 37280551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 52
Study 37280561 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful Activities and Recovery (MA&R) intervention
Number of subjects: 139
Study 37280561 — intervention group
Group type: COMPARATOR
Intervention: Standard mental health care
Number of subjects: 139
Study 37280584 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week remote supervised videoconference-based intervention, consisting of 2 weekly 45-min group sessions with progressive resistance exercises
Number of subjects: 130
Study 37280584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130
Study 37280635 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially deprived category (FDep5)
Number of subjects: 10078
Study 37280635 — intervention group
Group type: COMPARATOR
Intervention: Other categories of FDep
Number of subjects: 10078
Study 37280637 — intervention group
Group type: EXPERIMENTAL
Intervention: Global posture reeducation
Number of subjects: 40
Study 37280637 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental muscle stretching exercises
Number of subjects: 40
Study 37280638 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention package (CombinADO strategy)
Number of subjects: 59
Study 37280643 — intervention group
Group type: COMPARATOR
Intervention: Delpazolid 0 mg once daily for 16 weeks
Number of subjects: 75
Study 37280643 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 400 mg once daily for 16 weeks
Number of subjects: 75
Study 37280643 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg once daily for 16 weeks
Number of subjects: 75
Study 37280643 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 1200 mg once daily for 16 weeks
Number of subjects: 75
Study 37280643 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg twice daily for 16 weeks
Number of subjects: 75
Study 37280643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no delpazolid)
Number of subjects: 75
Study 37280688 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG) 300 mg
Number of subjects: 28
Study 37280688 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (LOV) 200 mg
Number of subjects: 28
Study 37280688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28